News Breaks |
|
|
| January 18, 2013 |
| 09:04 EDT |  | ABT, ABBV | CHMP adopts positive opinion recommending Abbott's Humira
The European Medicine Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending a variation to the terms of the marketing authorization for Abbott's Humira. Humira in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 2 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.Reference Link |
|
|
News For ABT;ABBV From The Last 14 Days Check below for free stories on ABT;ABBV the last two weeks. |
|
|
| May 21, 2013 |
| 08:03 EDT | | ABT | Abbott announces CE Mark for coronary drug eluting stent
 Subscribe for More Information |
|
| May 20, 2013 |
| 10:51 EDT | | ABBV | AbbVie initiates Phase 3 clinical study for atrasentan
Subscribe for More Information |
|
| 10:11 EDT |  | ABT | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 07:42 EDT |  | ABBV | Cohasset Associates to host a conference
National Conference on Managing Electronic Records is being held in Chicago on May 20-22. |
|
| 06:01 EDT | | ABT | Abbott upgraded to Buy from Neutral at Goldman
Goldman upgraded Abbott to reflect accelerating growth driven by emerging markets, better growth and product mix, new product launches, and market share gains. Price target raised to $44 from $38. |
|
| May 17, 2013 |
| 05:15 EDT | | ABBV | Galapagos, AbbVie extend GLPG0634 collaboration
Galapagos and AbbVie announced an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3. Upon successful completion of the study, expected in Q2 of 2015, AbbVie will pay Galapagos $50M. The terms of the collaboration extension are in addition to previously agreed upon financial terms. AbbVie will be responsible for funding and performing clinical development beyond Phase 2, and completing regulatory and commercialization activities. Galapagos will start an 20-week, Phase 2A/B study with GLPG0634 in 180 patients suffering from Crohn's disease by early 2014. |
|
| May 16, 2013 |
| 08:55 EDT | | ABBV | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| May 15, 2013 |
| 17:26 EDT | | ABBV | Third Point gives quarterly update on stakes
NEW STAKES: Virgin Media (VMED), Tiffany (TIF), B/E Aerospace (BEAV), Anadarko (APC), and Thermo Fisher (TMO). INCREASED STAKES: International Paper (IP), Abbvie (ABBV), TransDigm (TDG), Constellation Brands (STZ), and Dollar General (DG). DECREASED STAKES: Delphi (DLPH), Murphy Oil (MUR), AIG (AIG), LyondellBasell (LYB), and Liberty Global (LBTYA). LIQUIDATED STAKES: Tesoro (TSO), Morgan Stanley (MS), Symantec (SYMC), Herbalife (HLF), and Illumina (ILMN). |
|
| 10:13 EDT |  | ABBV | On The Fly: Analyst Initiation Summary
Subscribe for More Information |
|
| 07:59 EDT | | ABBV | AbbVie initiated with an Outperform at Cowen
Subscribe for More Information |
| |
| May 14, 2013 |
| 10:20 EDT |  | ABBV | AbbVie volatility at 22 into ASCO
Subscribe for More Information |
|
| 09:27 EDT | | ABBV | AbbVie and Alvine Pharmaceutical enter into collaboration
Subscribe for More Information |
|
| 07:24 EDT | | ABBV | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. |
|
| May 10, 2013 |
| 16:34 EDT | | ABBV | AbbVie chief scientific officer Leonard to retire
AbbVie disclosed in a regulatory filing that John Leonard, senior VP, chief scientific officer, has informed the company that he will be retiring from the company in the next few months and will be involved in the transition process for naming his successor. |
|
| May 9, 2013 |
| 07:04 EDT | | ABT | Abbott announces CE Mark for A1c test
Subscribe for More Information |
|
|
|
|
|
